BBBIOBridgeBio Pharma, Inc.

BridgeBio develops drugs for diseases with a known genetic cause.

The approach differs in how targets are chosen: the company takes on only conditions where the faulty gene is identified — the drug's mechanism is then understood in advance, and the probability of success is above the industry average. Programmes are run through separate subsidiaries with their own funding.

The lead drug stabilises the protein that deposits in heart muscle in hereditary amyloidosis — a condition diagnosed increasingly often as the relevant imaging spreads. The market here is large and already occupied by a competitor, so the outcome turns not only on efficacy but on convenience of dosing. The company pays no dividend.